Skip to contentO
Oncotelic Therapeutics, Inc.
O
OTLCOncotelic Therapeutics, Inc. Q3 2020 · 10-Q
Revenue$0.00$0.00derivedno prior Q3 2019 on file Net Income-$1.99M-$1.99MN/M vs Q3 2019 EPS Diluted-$0.02-$0.02N/M vs Q3 2019 Operating Income-$1,616,273N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oncotelic Therapeutics, Inc. · CIK 908259 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,583,257N/M ended Sep 30, 2020 · filed Nov 16, 2020 · 47 d after period end